Search Results

The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.

58020 Results Found

CDC updates clinical guidance on treating COVID-19 recurrence after antiviral pill

The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who receive

Medicaid enhances website to help beneficiaries renew coverage 

The update includes a button to help beneficiaries prepare to renew their coverage when the COVID-19 public health emergency ends.

AHA urges FTC to investigate certain pharmacy benefit manager practices 

AHA today urged the FTC to scrutinize commercial health plans that steer patients to third-party specialty pharmacies in which they have a financial interest.

CDC: U.S. births rose in 2021 for first time in 7 years

U.S. births rose 1% in 2021 to about 3.7 million, the first increase since 2014.
Public

[Special Edition]: Insurers’ “White Bagging” Drug Policy Threatens Patient Safety

Increases in consolidation and alignment between commercial health plans and pharmacy benefit managers have resulted in a series of business practices designed to steer patients to insurer-affiliated pharmacies and away from patients’ longstanding providers to the detriment of patient care.

Lunch & Learn Series: The Challenges with Decarbonization | Presented by Gordian

Speaker Mark Kenneday moderates a panel addressing this hot button issue in the healthcare space. If the US Healthcare System was its own country, it would be the 10th largest emitter of carbon emissions in the world! With Washington discussing policies to make decarbonization a focus for Hospitals, it's important to take a look at what can be done, and the challenges that will need to be addressed to make this a reality.
Public

AHA to FTC Re: Request for Public Comment on the Impact of Pharmacy Benefit Managers’ Practice

The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.